Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage

Carlos A.Q. Santos, Daniel Brennan, Mohammed J. Saeed, Victoria J. Fraser, Margaret A. Olsen

Research output: Contribution to journalArticle

Abstract

We assembled a cohort of 21 117 kidney transplant patients from July 2006 to June 2011 with Medicare Part D coverage using US Renal Database System data to determine real-world use of cytomegalovirus (CMV) prophylaxis. CMV prophylaxis was defined as filled prescriptions for daily oral valganciclovir (≤900 mg), ganciclovir (≤3 g), or valacyclovir (6-8 g) within 28 d of transplant. Multilevel logistic regression analyses were performed to determine factors associated with CMV prophylaxis. CMV prophylaxis (97% valganciclovir) was identified in 61% of kidney transplant recipients (median duration, 64 d); 71% of seronegative recipients of kidneys from seropositive donors (D+/R-); 63% of R+ patients; 60% of patients with unknown serostatus; and 34% of D-/R- patients. Variability in usage of prophylaxis among transplant centers was greater than variability within transplant centers. One in four transplant centers prescribed CMV prophylaxis to >60% of their D-/R- patients. CMV donor/recipient serostatus, lymphocyte-depleting agents for induction and mycophenolate for maintenance were associated with CMV prophylaxis. CMV prophylaxis was commonly used among kidney transplant recipients. Routine prescription of CMV prophylaxis to D-/R- patients may have occurred in some transplant centers. Limiting unnecessary use of CMV prophylaxis may decrease healthcare costs and drug-related harms.

Original languageEnglish (US)
Pages (from-to)435-444
Number of pages10
JournalClinical Transplantation
Volume30
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Medicare Part D
Pharmacoepidemiology
Cytomegalovirus
Kidney
Transplants
valacyclovir
Prescriptions
Transplant Recipients
Tissue Donors
Ganciclovir
Information Systems
Health Care Costs

Keywords

  • Cytomegalovirus
  • Kidney transplant
  • Pharmacoepidemiology

ASJC Scopus subject areas

  • Transplantation

Cite this

Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage. / Santos, Carlos A.Q.; Brennan, Daniel; Saeed, Mohammed J.; Fraser, Victoria J.; Olsen, Margaret A.

In: Clinical Transplantation, Vol. 30, No. 4, 01.04.2016, p. 435-444.

Research output: Contribution to journalArticle

Santos, Carlos A.Q. ; Brennan, Daniel ; Saeed, Mohammed J. ; Fraser, Victoria J. ; Olsen, Margaret A. / Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage. In: Clinical Transplantation. 2016 ; Vol. 30, No. 4. pp. 435-444.
@article{dac2b16051a7425d9849c67a9ddaba07,
title = "Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage",
abstract = "We assembled a cohort of 21 117 kidney transplant patients from July 2006 to June 2011 with Medicare Part D coverage using US Renal Database System data to determine real-world use of cytomegalovirus (CMV) prophylaxis. CMV prophylaxis was defined as filled prescriptions for daily oral valganciclovir (≤900 mg), ganciclovir (≤3 g), or valacyclovir (6-8 g) within 28 d of transplant. Multilevel logistic regression analyses were performed to determine factors associated with CMV prophylaxis. CMV prophylaxis (97{\%} valganciclovir) was identified in 61{\%} of kidney transplant recipients (median duration, 64 d); 71{\%} of seronegative recipients of kidneys from seropositive donors (D+/R-); 63{\%} of R+ patients; 60{\%} of patients with unknown serostatus; and 34{\%} of D-/R- patients. Variability in usage of prophylaxis among transplant centers was greater than variability within transplant centers. One in four transplant centers prescribed CMV prophylaxis to >60{\%} of their D-/R- patients. CMV donor/recipient serostatus, lymphocyte-depleting agents for induction and mycophenolate for maintenance were associated with CMV prophylaxis. CMV prophylaxis was commonly used among kidney transplant recipients. Routine prescription of CMV prophylaxis to D-/R- patients may have occurred in some transplant centers. Limiting unnecessary use of CMV prophylaxis may decrease healthcare costs and drug-related harms.",
keywords = "Cytomegalovirus, Kidney transplant, Pharmacoepidemiology",
author = "Santos, {Carlos A.Q.} and Daniel Brennan and Saeed, {Mohammed J.} and Fraser, {Victoria J.} and Olsen, {Margaret A.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1111/ctr.12706",
language = "English (US)",
volume = "30",
pages = "435--444",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage

AU - Santos, Carlos A.Q.

AU - Brennan, Daniel

AU - Saeed, Mohammed J.

AU - Fraser, Victoria J.

AU - Olsen, Margaret A.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - We assembled a cohort of 21 117 kidney transplant patients from July 2006 to June 2011 with Medicare Part D coverage using US Renal Database System data to determine real-world use of cytomegalovirus (CMV) prophylaxis. CMV prophylaxis was defined as filled prescriptions for daily oral valganciclovir (≤900 mg), ganciclovir (≤3 g), or valacyclovir (6-8 g) within 28 d of transplant. Multilevel logistic regression analyses were performed to determine factors associated with CMV prophylaxis. CMV prophylaxis (97% valganciclovir) was identified in 61% of kidney transplant recipients (median duration, 64 d); 71% of seronegative recipients of kidneys from seropositive donors (D+/R-); 63% of R+ patients; 60% of patients with unknown serostatus; and 34% of D-/R- patients. Variability in usage of prophylaxis among transplant centers was greater than variability within transplant centers. One in four transplant centers prescribed CMV prophylaxis to >60% of their D-/R- patients. CMV donor/recipient serostatus, lymphocyte-depleting agents for induction and mycophenolate for maintenance were associated with CMV prophylaxis. CMV prophylaxis was commonly used among kidney transplant recipients. Routine prescription of CMV prophylaxis to D-/R- patients may have occurred in some transplant centers. Limiting unnecessary use of CMV prophylaxis may decrease healthcare costs and drug-related harms.

AB - We assembled a cohort of 21 117 kidney transplant patients from July 2006 to June 2011 with Medicare Part D coverage using US Renal Database System data to determine real-world use of cytomegalovirus (CMV) prophylaxis. CMV prophylaxis was defined as filled prescriptions for daily oral valganciclovir (≤900 mg), ganciclovir (≤3 g), or valacyclovir (6-8 g) within 28 d of transplant. Multilevel logistic regression analyses were performed to determine factors associated with CMV prophylaxis. CMV prophylaxis (97% valganciclovir) was identified in 61% of kidney transplant recipients (median duration, 64 d); 71% of seronegative recipients of kidneys from seropositive donors (D+/R-); 63% of R+ patients; 60% of patients with unknown serostatus; and 34% of D-/R- patients. Variability in usage of prophylaxis among transplant centers was greater than variability within transplant centers. One in four transplant centers prescribed CMV prophylaxis to >60% of their D-/R- patients. CMV donor/recipient serostatus, lymphocyte-depleting agents for induction and mycophenolate for maintenance were associated with CMV prophylaxis. CMV prophylaxis was commonly used among kidney transplant recipients. Routine prescription of CMV prophylaxis to D-/R- patients may have occurred in some transplant centers. Limiting unnecessary use of CMV prophylaxis may decrease healthcare costs and drug-related harms.

KW - Cytomegalovirus

KW - Kidney transplant

KW - Pharmacoepidemiology

UR - http://www.scopus.com/inward/record.url?scp=84959468076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959468076&partnerID=8YFLogxK

U2 - 10.1111/ctr.12706

DO - 10.1111/ctr.12706

M3 - Article

VL - 30

SP - 435

EP - 444

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4

ER -